Could Semaglutide treat addiction as well as obesity?
Could glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide — approved as Ozempic to treat type 2 diabetes and as Wegovy to treat obesity, also
Could glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide — approved as Ozempic to treat type 2 diabetes and as Wegovy to treat obesity, also
Bigfoot’s diabetes management system is designed to address problems such as missed doses, inadequate insulin intensification and dosing errors that affect people with diabetes who
Sernova has entered into a preclinical research collaboration on drug delivery with AstraZeneca, with the aim of evaluating the use of Sernova’s Cell Pouch System
Hundreds of British children with Type 2 diabetes who currently manage their condition with ‘burdensome’ finger prick blood testing several times a day could be
A potential stem cell–derived pancreatic islet cell replacement therapy (VX-880, from Vertex Pharmaceuticals) continues to show promise as a treatment for Type 1 diabetes, according
Substantial reductions in body weight across body mass index (BMI) categories, as well as improved body composition, were achieved with tirzepatide (Mounjaro) in adults for
A new study commissioned by Dexcom has found that 84% of people surveyed agreed that having diabetes can negatively impact mental health. The study also
Diabetes UK (DUK) has marked Diabetes Week by launching a campaign to call for fair and equal access to diabetes tech. A recent DUK press
A new guideline from the World Health Organization (WHO) on nonsugar sweeteners (NSSs) recommends not using them to control weight or to reduce the risk
A £5m funding award has been given to three researchers that have worked with DRWF. The funding marks the start of the Type 1 Diabetes